Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Consolidation in ESCC
NCT03817658Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Oct 2019
- Primary completion
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03817658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817658.